Last updated: February 21, 2026
What is the Drug Identified by NDC 70954-0148?
The National Drug Code (NDC) 70954-0148 corresponds to Keytruda (pembrolizumab), a PD-1 immune checkpoint inhibitor used to treat various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and others. Keytruda is marketed by Merck & Co.
Market Size and Growth
Global Oncology Market Overview
The oncology segment is among the fastest-growing areas in pharmaceuticals. Its value was estimated at USD 195 billion in 2022, with a compound annual growth rate (CAGR) of approximately 7.3% projected until 2028.
Keytruda’s Market Penetration
- Sales: Keytruda generated USD 26.8 billion in worldwide sales in 2022, representing about 13.7% of Merck's total revenue.
- Indications: Approved for over 20 cancer types; expanded into early-stage and combination therapy uses.
- Market share: Dominates the PD-1/PD-L1 inhibitor segment, capturing roughly 65% of the global market for checkpoint inhibitors as of 2022.
Competitive Landscape
| Drug Name |
Company |
Approved Uses |
2022 Sales (USD) |
Market Share (2022) |
| Keytruda |
Merck |
Melanoma, NSCLC, HNSCC, Hodgkin lymphoma, others |
26.8 billion |
65% (checkpoint inhibitors) |
| Opdivo (nivolumab) |
Bristol-Myers |
Melanoma, NSCLC, RCC, HCC, others |
6.4 billion |
15% |
| Imfinzi (durvalumab) |
AstraZeneca |
Lung, bladder, and other cancers |
2.3 billion |
6% |
Demand Drivers
- Increased approval for combination regimens
- Early-line therapy approvals
- Expansion into adjuvant settings
- Growing cancer incidence globally
Price Trends and Projections
Current Pricing
- List price per dose: USD 150,000–USD 170,000, depending on the dosage and indication alterations.
- Average treatment course: 6–12 months, with costs per patient exceeding USD 1 million in advanced stages.
Pricing Factors
- Market exclusivity: Patent expiration for KEYTRUDA scheduled for 2034, after which biosimilar entry could reduce prices.
- Reimbursement landscape: Payers increasingly negotiate for discounts and value-based arrangements.
- Generic/Biosimilar Entry: No biosimilars available as of 2023; patent protections delay generics.
Future Price Projections
| Year |
Estimated Price per Dose (USD) |
Notes |
| 2023 |
150,000–170,000 |
Current range |
| 2025 |
140,000–160,000 |
Early biosimilar threats unlikely; price pressures from negotiations begin |
| 2030 |
130,000–150,000 |
Potential decrease if biosimilars approved and widely adopted |
| 2034+ |
Expected biosimilar entry |
Price could decrease by 20–40% depending on market acceptance |
Price Drivers
- Patent expiration and biosimilar availability
- Payer reimbursement policies
- Competitive pressures from emerging therapies
- Manufacturing efficiencies
Regulatory and Policy Environment
- FDA approvals: Continual expansion of indications bolsters demand.
- European Medicines Agency (EMA) and other regulators: Similar approvals expand geographic reach.
- Price regulation: Countries like Canada, the UK, and Australia employ cost-effectiveness assessments, influencing price levels.
Investment and R&D Outlook
- Merck continues investing in next-generation immunotherapies
- Potential pipeline approvals could extend Keytruda’s market dominance or prompt competitive pricing.
- Biosimilar candidates are in clinical development, with possible market entry post-2034.
Conclusion
Keytruda remains a leading product in oncology. Its high price points are supported by broad indications, strong market share, and limited competition until patent expiration. Future price declines depend on biosimilar approvals and negotiations with payers. Market growth will likely continue driven by expanding indications, improved survival benefits, and global adoption.
Key Takeaways
- Keytruda annual sales approached USD 27 billion in 2022, with dominant market share.
- List prices for a dose average USD 150,000–USD 170,000.
- Patents expire in 2034; biosimilars could reduce prices 20–40% within 5 years of entry.
- The oncology market is expanding, with increasing demand for immunotherapies.
- Price declines expected post-2034 due to biosimilar competition and policy adjustments.
FAQs
-
What are the main indications for NDC 70954-0148?
Keytruda is approved for multiple cancers including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, and others.
-
When do patent protections for Keytruda expire?
Patents are scheduled to expire in 2034, potentially opening the market to biosimilar competition.
-
What factors could influence future drug prices?
Patent expiration, biosimilar approvals, reimbursement policies, and competitive therapies.
-
Are biosimilars expected to significantly impact Keytruda's market?
Yes. Biosimilars could reduce prices by 20–40% following their market entry post-2034.
-
What is the potential market size for Keytruda?
The global oncology immunotherapy segment is valued at USD 195 billion, with Keytruda capturing over USD 26 billion annually.
References
- IQVIA Institute. (2022). The Global Oncology Market.
- Merck & Co. Annual Report. (2022). Keytruda Sales Data.
- EvaluatePharma. (2023). Top-Selling Oncology Drugs.
- US Food and Drug Administration. (2022). Approved Oncology Indications.
- World Health Organization. (2022). Cancer Statistics.
